Embase Search terms:
#1 esophagogastric junction tumours either proximal, total, or distal subtotal gastrectomy was recommended with a lymphadenectomy to include as a minimum lymph node stations 1-7 to ensure at least 15 nodes were excised; for Siewert type II esophagogastric junction tumours, either extended gastrectomy or two-phase esophago-gastrectomy with a two-field lymphadenectomy; for Siewert type I esophagogastric junction or lower oesophageal tumours, esophagogastrectomy with either a two phase right thoraco-abdominal approach or a left thoracoabdominal approach with a two field lymphadenectomy. Minimal access procedures were allowed only in centres that had sufficient experience (at least 20 such procedures done) after review of outcomes and complication rates by surgeons from the Trial Management Group. Systemic treatments: Epirubicin, cisplatin, and capecitabine chemotherapy was given as three preoperative and three post-operative 21-day cycles, consisting of 50 mg/m2 intravenous epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1-21. Patients in the chemotherapy plus bevacizumab group were given 7·5 mg/kg bevacizumab as a continuous intravenous infusion on day 1 of each of the chemotherapy cycles (either before or after the chemotherapy was given). To maximise any potential treatment effect with an acceptable toxicity profile, patients in the bevacizumab group also received six further infusions of bevacizumab alone (7·5 mg/kg intravenously alone every 21 days) as maintenance treatment after post-operative chemotherapy.
Noh 2014
Surgical details: All patients had curative D2 gastrectomy within 6 weeks before randomization. At least 15 lymph nodes were examined to ensure adequate disease classification. All surgeons had experience doing this type of surgery (>50 procedures per year). To further ensure the quality of surgery, standard operating procedures were predefined and given to all surgeons before the start of the study, and surgery was photographed.
Systemic treatments: Patients assigned to the chemotherapy group received eight 3-week cycles of oral capecitabine (1000 mg/m2 twice daily on days 1-14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle).
Ychou 2011
Surgical details: Surgery was scheduled within 4 weeks after random assignment in the S group and 4 to 6 weeks after completion of the last cycle of chemotherapy in the CS group. Surgery consisted in a complete excision of the tumor with an extended lymphadenectomy (D2 recommended). The local surgeon decided the surgical procedure in accordance with the site of the tumor and local practice.
Systemic treatments: According to tumor response and safety, chemotherapy comprised two or three preoperative cycles of FU 800 mg/m2/d as continuous intravenous (IV) infusion for 5 consecutive days (days 1 to 5) and cisplatin 100 mg/m2 as a 1-hour infusion, every 28 days, and 3 to 4 postoperative cycles in case of good tolerance and no evidence of progressive disease after preoperative chemotherapy, for a total of 6 cycles.
Cunningham 2006
Surgical details: In radical total gastrectomy, the whole stomach was removed, with the proximal line of division through the distal esophagus, and the distal line of division through the proximal duodenum. The resection also included the greater and lesser omenta and any other organs involved by extension of the primary growth (e.g., pancreas, spleen, mesocolon, colon, or left lobe of liver). The procedure for a radical subtotal distal gastrectomy was the same, but a small, viable gastric remnant was left intact. In both procedures, the resection lines had to be at least 3 cm from the edge of the macroscopic tumor. The surgeon decided the extent of the lymph-node dissection. Lymph nodes along the lesser and greater curvatures and at the origin of the left gastric artery were to be included.
Systemic treatments: Chemotherapy was administered for three cycles preoperatively and three cycles postoperatively. Each 3-week cycle consisted of epirubicin (50 mg per square meter of body-surface area) by intravenous bolus on day 1, cisplatin (60 mg per square meter) intravenously with hydration on day 1, and fluorouracil (200 mg per square meter) daily for 21 days by continuous intravenous infusion with the use of a double-lumen Hickman catheter and a portable infusion pump.
MRCOCWG 2002
Surgical details: For patients in CS group, surgical resection was done 3-5 weeks after the start of the second cycle of chemotherapy, and for patients in the S group, surgery was done as soon as possible after randomization. The local surgeon decided the surgical procedure for patients in both treatment groups, in accordance with site of the tumor and local practice.
Systemic treatments: Chemotherapy comprised two 4-day cycles of cisplatin 80 mg/m2 by intravenous infusion over 4 h on day 1 and fluorouracil 1000 mg/m2 daily as a continuous infusion over 96 h, with an interval of 3 weeks between the first day of each cycle. No subgroup survival data of junctional cases Tsavaris 1996 74 No subgroup survival data of junctional cases Neri 1996 75 No subgroup survival data of junctional cases Macdonald 1995 76 No subgroup survival data of junctional cases Lise 1995 77 No subgroup survival data of junctional cases Hallissey 1994 78 No subgroup survival data of junctional cases Arima 1994 79 No subgroup survival data of junctional cases Grau 1993 80 No subgroup survival data of junctional cases Fok 1993 81 No subgroup survival data of junctional cases Nygaard 1992 82 No subgroup survival data of junctional cases Krook 1991 83 No subgroup survival data of junctional cases Kelsen 1990 84 No subgroup survival data of junctional cases Coombes 1990 85 No subgroup survival data of junctional cases Bleiberg 1989 86 No subgroup survival data of junctional cases Allum 1989 87 No subgroup survival data of junctional cases Roth 1988 88 No subgroup survival data of junctional cases Iizuka 1988 89 No subgroup survival data of junctional cases Nakajima 1984 90 No subgroup survival data of junctional cases Moertel 1984 91 No 
